What is Impel Pharmaceuticals Inc. (IMPL)?

Impel Pharmaceuticals Inc. (IMPL) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of IMPL?

The current price of IMPL is $0.04. Prices are updated in real time on Stocks360.

What is IMPL's price-to-earnings (PE) ratio?

IMPL's trailing twelve-month PE ratio is -0.01, based on current price and earnings per share data available on Stocks360.

What is IMPL's market capitalization?

IMPL's market capitalization is $956,000.00, placing it in the small-cap tier.

Impel Pharmaceuticals Inc. (IMPL)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$0.04

Market Cap

$956.00K

PE (TTM)

-0.01

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.17

Day Range

$0.02 – $0.05

52-wk Range

$0.02 – $4.20

Avg Volume

N/A

Volume

720.03K

Impel Pharmaceuticals Inc. (IMPL) is a publicly traded company in the Healthcare sector. Latest price: $0.04. Market cap $956.00K. Trailing PE -0.01. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Nov 14, 2023

EPS $-0.58 vs est. $-0.36

Missed by $0.22

Proprietary Signals

Signal snapshot temporarily unavailable.

About Impel Pharmaceuticals Inc.

Impel Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical firm, concentrating its efforts on creating and commercializing therapies for individuals in the United States who are affected by central nervous system (CNS) conditions. Leading its product portfolio is Trudhesa, an innovative upper nasal formulation of dihydroergotamine, specifically engineered for the prompt relief of acute migraine attacks. Furthermore, the company's development pipeline encompasses INP105, another upper nasal medication containing olanzapine, currently being advanced for the rapid treatment of agitation and aggressive behaviors associated with autism spectrum disorder. Impel is also progressing with INP107, an intranasal carbidopa/levodopa compound, which has already successfully concluded its Phase IIa clinical trial aimed at managing "OFF" episodes in Parkinson's disease patients. Initially established in 2008, the company was formerly known as Impel NeuroPharma, Inc. before rebranding to Impel Pharmaceuticals Inc. in April 2022. Its corporate headquarters are situated in Seattle, Washington.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.01×
P/S (TTM)	0.08×
P/B	-0.02×
P/FCF (TTM)	-0.01×
EV / EBITDA	0.09×
EV / Sales	-0.67×
Earnings Yield	-13802.46%
Free Cash Flow Yield	-9939.23%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$8.51M
Net Income (TTM)	-$131.95M
Free Cash Flow (TTM)	-$78.17M
Net Debt	-$9.47M
Working Capital	$57.65M
Gross Margin	48.66%
Operating Margin	-657.48%
Net Margin	-1023.08%
Return on Equity	-3099.99%
Return on Invested Capital	-122.46%